| Dataset | GWASdb SNP-Phenotype Associations |
| Category | disease or phenotype associations |
| Type | phenotype |
| Description | A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.|Tumors or cancer of the LIVER.|A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation. --2002|A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation. (Experimental Factor Ontology, EFO_0000182) |
| External Link | http://jjwanglab.org/gwasdb/gwasdb2/gwasdb2/go_trait/HP:0001402 |
| Similar Terms | |
| Downloads & Tools |
29 genes associated with the hepatocellular carcinoma phenotype in GWAS datasets from the GWASdb SNP-Phenotype Associations dataset.
| Symbol | Name | Standardized Value |
|---|---|---|
| HLA-DPA1 | major histocompatibility complex, class II, DP alpha 1 | 2.67061 |
| HLA-DPB1 | major histocompatibility complex, class II, DP beta 1 | 2.59698 |
| HLA-DQB2 | major histocompatibility complex, class II, DQ beta 2 | 2.17144 |
| KIF1B | kinesin family member 1B | 1.8904 |
| C2 | complement component 2 | 1.8533 |
| HLA-DQB1 | major histocompatibility complex, class II, DQ beta 1 | 1.65108 |
| DEPDC5 | DEP domain containing 5 | 1.62688 |
| MICA | MHC class I polypeptide-related sequence A | 1.59332 |
| STAT4 | signal transducer and activator of transcription 4 | 1.44129 |
| GRIK1 | glutamate receptor, ionotropic, kainate 1 | 1.37994 |
| GRIN2A | glutamate receptor, ionotropic, N-methyl D-aspartate 2A | 1.22817 |
| HLA-DQA1 | major histocompatibility complex, class II, DQ alpha 1 | 1.15618 |
| MTMR6 | myotubularin related protein 6 | 1.12851 |
| LRP1B | low density lipoprotein receptor-related protein 1B | 1.03995 |
| EFCAB11 | EF-hand calcium binding domain 11 | 0.942765 |
| CHD6 | chromodomain helicase DNA binding protein 6 | 0.932707 |
| ABTB2 | ankyrin repeat and BTB (POZ) domain containing 2 | 0.851815 |
| BACH2 | BTB and CNC homology 1, basic leucine zipper transcription factor 2 | 0.844241 |
| CD163L1 | CD163 molecule-like 1 | 0.82221 |
| SYNJ2BP | synaptojanin 2 binding protein | 0.740664 |
| PC | pyruvate carboxylase | 0.717942 |
| THSD7A | thrombospondin, type I, domain containing 7A | 0.681114 |
| PODXL | podocalyxin-like | 0.642942 |
| ADCY10 | adenylate cyclase 10 (soluble) | 0.632852 |
| CASC15 | cancer susceptibility candidate 15 (non-protein coding) | 0.630475 |
| C6ORF7 | chromosome 6 open reading frame 7 | 0.613457 |
| AJAP1 | adherens junctions associated protein 1 | 0.611781 |
| ZHX2 | zinc fingers and homeoboxes 2 | 0.575216 |
| TMTC1 | transmembrane and tetratricopeptide repeat containing 1 | 0.517271 |
